Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$225.81 USD

225.81
192,280

+1.20 (0.53%)

Updated Jul 5, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab

by Zacks Equity Research

Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

by Zacks Equity Research

Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

by Zacks Equity Research

The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.

La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day.

Kinjel Shah headshot

Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?

by Kinjel Shah

Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.

Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?

by Zacks Equity Research

Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.

Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sanghamitra Saha headshot

Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

by Sanghamitra Saha

On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

by Zacks Equity Research

Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

by Zacks Equity Research

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)

by Zacks Equity Research

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune

by Zacks Equity Research

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

Kinjel Shah headshot

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

by Kinjel Shah

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

by Zacks Equity Research

Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.

Mark Vickery headshot

Apple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug

by Mark Vickery

Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance

by Zacks Equity Research

FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

by Zacks Equity Research

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?

by Zacks Equity Research

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

by Zacks Equity Research

Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.

Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

by Zacks Equity Research

Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe

Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?

by Zacks Equity Research

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.